A recent retrospective cohort study delved into the clinical efficacy of amlodipine treatment post-hospitalization for heart failure in individuals with dilated cardiomyopathy (DCMP). Examining 20,851 patients diagnosed with DCMP and admitted for heart failure between 2005 and 2016, the study utilized the Korean nationwide medical insurance service database. Amlodipine usage, defined as prescribed at discharge and continued for a minimum of 180 days within a year, demonstrated a substantial reduction in the risk of all-cause death and heart failure rehospitalization over 5 years compared to non-amlodipine users. Subgroup analysis indicated particular efficacy in older adults, those with elevated systolic blood pressure, and individuals with a lower Charlson Comorbidity Index.
Like
Save
Share